Terumo India has launched the FineCross M3 coronary micro-guide catheter, designed for improved performance in complex percutaneous coronary interventions (PCI), especially when dealing with tortuous or tight coronary lesions.
Glimpse:
The FineCross M3 is a next generation micro guide catheter now available in India. It offers superior crossing ability, better guidewire support, and enhanced navigability, helping interventional cardiologists manage challenging coronary anatomies more effectively. Key features include a tapered distal tip, a floppy distal segment, hydrophilic coating, and radiopaque markers to enhance visibility under imaging.
Terumo India has officially launched the FineCross M3 Coronary Micro-Guide Catheter in India, marking a significant upgrade to its interventional cardiology portfolio.
The FineCross M3 is engineered to address real-world challenges in PCI procedures, especially in patients with complex coronary lesions. It is designed with a 1.7 Fr tapered distal tip for easier crossing of restrictive lesions, a 15 cm floppy distal segment to enhance trackability in tortuous vessel paths, and a tapered stainless steel braided shaft for improved pushability and control. It also includes a next-generation hydrophilic coating for lubrication and reduced friction, a PTFE inner layer, and radiopaque markers for precise imaging.
Shishir Agarwal, President & Managing Director of Terumo India, said this launch is consistent with Terumo’s commitment to bringing globally trusted innovations to Indian cardiac care, reinforcing its mission of “unwavering commitment to patients.”
Nitin Stephen Abel, Senior Director of Terumo India’s Interventional Systems, highlighted that the FineCross M3 will enable more efficient, predictable, and safer procedures in complex PCI cases, helping clinicians improve outcomes even in difficult anatomies.
This product adds to Terumo India’s advanced device offerings for cardiovascular care, supporting the growing burden of coronary artery disease in India, where many patients present with complex or tortuous lesions.
“With the launch of FineCross M3, we are proud to bring a globally trusted advancement in interventional cardiology to India. This milestone reflects not only our commitment to strengthening cardiovascular care in the country, but also our promise to patients.”
By
HB Team
